We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

BD Sells Surgical Instrumentation Platform to STERIS

By HospiMedica International staff writers
Posted on 21 Jun 2023
Print article
Image: The divestiture of the surgical instrumentation platform includes V. Mueller, Snowden-Pencer and Genesis branded products (Photo courtesy of BD)
Image: The divestiture of the surgical instrumentation platform includes V. Mueller, Snowden-Pencer and Genesis branded products (Photo courtesy of BD)

Becton, Dickinson and Company (BD, Franklin Lakes, NJ, USA) has signed a definitive agreement to sell its Surgical Instrumentation platform to STERIS (Mentor, OH, USA) for USD 540 million. The divestiture includes the transfer of V. Mueller, Snowden-Pencer, and Genesis branded products as well as three manufacturing facilities.

STERIS is a global provider of products and services that support patient care, particularly in the field of infection prevention. It offers a wide range of infection prevention products and other procedural services, mainly aimed at healthcare, pharmaceutical, medical device, and dental clients. The acquisition of BD's surgical instrumentation platform, which complements STERIS's Healthcare segment, will empower STERIS to more effectively meet the product and service demands of hospitals and surgery centers. The platform has three dedicated manufacturing sites and about 20,000 SKUs in its portfolio. The divestment of its Surgical Instrumentation platform aligns with the "Simplify" objective of BD's 2025 strategy and represents a significant move towards streamlining its product portfolio and manufacturing network.

"The Surgical Instrumentation platform has a 120-year legacy of providing reliable and trusted high-quality products, and STERIS is well positioned to maximize the value of this extensive portfolio and is fortunate to be adding such a dedicated and talented team to its organization," said Rick Byrd, president of the Interventional segment at BD. "This transaction further advances the BD Interventional segment's focus on high-growth end markets. We look forward to continuing to address unmet needs in health care through a highly differentiated and innovative set of solutions and products."

Related Links:
Becton, Dickinson and Company 
STERIS 

Gold Member
12-Channel ECG
CM1200B
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
New
Rapid Cleaning Verification Tool
ProExpose Protein Detection Test
New
Surgical Positioning Accessory
Lateral Support Curved Short (10-360)

Print article

Channels

Critical Care

view channel
Image: Mesenchymal stromal cells are delivered directly into the lungs using a bronchoscope (Photo courtesy of Stem Cell Res Ther. 2025. DOI: 10.1186/s13287-025-04289-3)

Novel Intrabronchial Method Delivers Cell Therapies in Critically Ill Patients on External Lung Support

Until now, administering cell therapies to patients on extracorporeal membrane oxygenation (ECMO)—a life-support system typically used for severe lung failure—has been nearly impossible.... Read more

Surgical Techniques

view channel
Image: Intravascular imaging can improve outcomes for complex stenting procedures in patients with high-risk calcified coronary artery disease (Photo courtesy of Shutterstock)

Intravascular Imaging for Guiding Stent Implantation Ensures Safer Stenting Procedures

Patients diagnosed with coronary artery disease, which is caused by plaque accumulation within the arteries leading to chest pain, shortness of breath, and potential heart attacks, frequently undergo percutaneous... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more